Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Pembrolizumab in Hematologic Malignancies
NCT02362035Phase 2Completed
- Sponsor
- Acerta Pharma
- Start
- Feb 2015
- Primary completion
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of acalabrutinib tablet (Variant 1), pembrolizumab in follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Richter's syndrome (RS), mantle cell lymphoma (MCL), sponsored by Acerta Pharma. Started Feb 2015; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)pembrolizumab
03
Conditions
follicular lymphoma (FL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)Richter's syndrome (RS)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02362035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362035.